Welcome
Support Centre
23 May 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Laparoscopic Gastric Bypass Versus Sleeve Gastrectomy to Treat Morbid Obesity
Link to the ClinicalTrials.gov recordInformation obtained from ClinicalTrials.gov on February 23, 2012
Title of trial/grant titleLaparoscopic Gastric Bypass Versus Sleeve Gastrectomy to Treat Morbid Obesity
Current status of trialCompleted
Sponsors and collaboratorsTurku University Hospital
Vaasa Central Hospital, Vaasa, Finland
Peijas Hospital, Helsinki
Information provided byTurku University Hospital
ClinicalTrials.gov identifierNCT00793143
PurposeBariatric surgery in the treatment of morbid obesity is associated with long-term
weight-loss and decreased overall mortality. Long-term results have been reported for
laparoscopic gastric bypass procedures but the long-term results of laparoscopic sleeve
gastrectomy are yet unavailable. As sleeve gastrectomy is a rapid and less traumatic
procedure with good short-term results of weight loss and resolution of comorbidities, the
investigators initiated a prospective randomized two-center study comparing laparoscopic
sleeve gastrectomy (LSG)with laparoscopic gastric bypass (LGB) in the treatment of morbid
obesity. Study hypothesis: As sleeve gastrectomy is less traumatic, easier and faster to
perform compared with gastric bypass,LSG could become the procedure of choice to treat
morbid obesity if the long-term results of weight loss and resolution of comorbidities are
comparable with laparoscopic gastric bypass.
Condition(s)Morbid Obesity
PhaseN/A
Study type and designObservational Model: Cohort, Time Perspective: Prospective
Official titleA Randomized Prospective Three-center Study: Laparoscopic Gastric Bypass vs. Laparoscopic Sleeve Gastrectomy in the Treatment of Morbid Obesity
Further study detailsIn addition to comparing the outcomes between sleeve gastrectomy and gastric bypass, the
study project includes a PET trial conducted in Turku. The objectives of this PET study are
to measure effect of obesity on food-stimuli mediated brain activation response and on
hormones affecting both feeding and energy balance. In the second part the same variables
are studied after bariatric surgery: either laparoscopic sleeve gastrectomy or Roux-en-Y
gastric bypass. In addition the effect of weight loss due to bariatric surgery on glucose
uptake and free fatty acid metabolism is measured. The objective is also to study whether
less invasive sleeve gastrectomy is as beneficial in terms of weight loss and co-morbid
diseases as more invasive Roux-en-Y gastric bypass and to compare the risk factors between
these two surgical procedures. Regional glucose uptake and free fatty acid uptake in
myocardium, skeletal muscle, subcutaneous fat, visceral fat, pancreas, liver and brain are
studied with PET at baseline before bariatric surgery and post-operatively on the 3rd month.
Changes in body fat distribution, in ectopic fat and fat content of key organs are
investigated with magnetic resonance imaging (MRI) and magnetic resonance spectroscopy
(MRS). Brain reward system response to food stimuli is assessed using functional MRI (fMRI)
and white and grey matter volumes using diffusion tensor imaging (DTI).

The study consists of 80 morbidly obese adults, BMI â¿¥ 40 kg/m2 or if there is additional
risk factor BMI â¿¥ 35 kg/m2. From these subjects, 40 are further studied with positron
emission tomography (PET) and magnetic resonance imaging (MRI). In addition functional MRI
(fMRI) will be performed for 40 subjects. For fMRI, a control group is recruited consisting
of 20 lean and healthy subjects. Subjects are physically examined and anthropometric data
are measured along with blood sampling.
Primary outcomeResolution of comorbidities 3,6,12,18 months, 2,3,5,7,10,15 years No
Secondary outcomeExcessive weight loss 3,6,12,18 months, 2,3,5,7,10,15 years No
Mortality 0 - 15 years Yes
Morbidity 0 - 15 years Yes
QOL (15D and BAROS) 3,6,12,18 months, 2,3,5,7,10,15 years No
Study startApril 2008
Minimum age18 Years
Maximum age60 Years
GenderBoth
Eligibility criteriaInclusion Criteria:

- BMI > 40 or BMI > 35 with a comorbidity associated with obesity

- Age 18 - 60 years

- Failed prior effective and controlled conservative treatments of morbid obesity

Exclusion Criteria:

- BMI > 60

- Difficult psychiatric conditions or lack of co-operation

- Difficult eating disorder (binge eating, bulimia etc.)

- Alcohol abuse

- Gastric ulcer
Study chairs or principal investigatorsPaulina Salminen, MD, PhD, Principal Investigator, Turku Univeristy Central Hospital
Jari Ovaska, Md, PhD, Principal Investigator, University of Turku
Mikael Victorzon, MD, PhD, Principal Investigator, Vaasa Central Hospital, Vaasa, Finland
LocationsFinland

Department of Surgery, Turku University Central Hospital
Turku
20520

Finland

Turku University Hospital, PET-center
Turku

Finland

Vaasa Central Hospital
Vaasa

Finland

Peijas Hospital
Vantaa
Study ID numbersSLEEVEPASS
Last updatedMay 24, 2010
Record first receivedNovember 17, 2008
ClinicalTrials.gov identifierNCT00793143
Download dateInformation obtained from ClinicalTrials.gov on February 23, 2012
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement | cookies


BioMed Central